VSEOBECNA FAKULTNI NEMOCNICE V PRAZE

Their core work

The General University Hospital in Prague is one of the Czech Republic's largest teaching hospitals, combining clinical care with clinical research across multiple medical disciplines. Within H2020, they contribute patient cohorts, clinical trial infrastructure, and medical expertise to European multi-centre studies — particularly in cardiovascular disease, oncology, tobacco cessation, and paediatric medicine. Their participation spans adult and paediatric populations, making them a versatile clinical partner for health-focused research consortia.

What they specialise in

How they've shifted over time

Early H2020 involvement (2015) centred on cardiovascular disease — specifically polypill strategies, medication adherence, and secondary prevention after myocardial infarction. By 2017-2018, the hospital's focus shifted toward oncology (BRCA-related cancers, early detection) and paediatric medicine (drug development infrastructure for children). This broadening from a single therapeutic area toward multiple clinical specialities reflects the hospital's general university character and its capacity to contribute across diverse medical fields.

Moving from single-disease clinical trials toward participation in large pan-European clinical infrastructure networks, suggesting growing interest in multi-disease platform roles.

How they like to work

Exclusively a participant or third party — never a coordinator in H2020, indicating they contribute clinical expertise and patient access rather than leading project design. With 80 unique partners across 23 countries from just 4 projects, they operate within very large consortia (averaging 20+ partners per project). This makes them an experienced member of big European networks, comfortable working within complex multi-site clinical studies.

Despite only 4 projects, they have collaborated with 80 unique partners across 23 European and international countries — a result of joining large clinical trial consortia. Their network is broad but consortium-driven rather than built through repeated bilateral partnerships.

What sets them apart

As a major Czech teaching hospital, they offer something many research institutes cannot: direct access to diverse patient populations and clinical infrastructure for multi-centre trials. Their spread across cardiovascular, oncology, paediatric, and respiratory medicine means they can serve as a clinical site for a wide range of health studies. For consortium builders needing a Central European clinical partner with experience in large EU trials, they are a proven and reliable choice.

Highlights from their portfolio

• SECURE
  Largest funded project (EUR 219,884) — a major multi-centre clinical trial on polypill-based cardiovascular prevention in elderly patients.
• c4c
  Part of a flagship pan-European network building clinical trial infrastructure specifically for paediatric medicines — a high-impact, long-running initiative (2018-2025).
• BRCA-ERC
  ERC Advanced Grant project investigating fundamental cancer biology in BRCA mutation carriers — signals involvement in frontier research beyond routine clinical work.